Inderjit Mehmi

8PUBLICATIONS
107CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)NanomedicineMedical devicesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 02, 2026
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.

|Oct 01, 2026
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

|Aug 18, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

|Feb 16, 2026
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Jan 10, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Juan Alban, R Christopher Bowen, David A Reichstein

|Jan 09, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.

Sylvia M Lee, Omid Hamid, Robert Jotte

Pageof 2

Frequent Collaborators

5 joint publications

Omid Hamid

2 joint publications

Sunandana Chandra

2 joint publications

Theresa Medina

1 joint publications

V Ekström-Rydén